Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2019 Aug 21:2019:5354320.
doi: 10.1155/2019/5354320. eCollection 2019.

Factors Influencing Disability and Quality of Life during Treatment: A Cross-Sectional Study on IBD Patients

Carla Marinelli  1 , Edoardo Savarino  1 , Marco Inferrera  1 , Greta Lorenzon  1 , Alessandra Rigo  1 , Matteo Ghisa  1 , Sonia Facchin  1 , Renata D'Incà  1 , Fabiana Zingone  1
Affiliations

Factors Influencing Disability and Quality of Life during Treatment: A Cross-Sectional Study on IBD Patients

Carla Marinelli et al. Gastroenterol Res Pract. .

Abstract

Background/aim: Inflammatory bowel disease (IBD) is a chronic disorder affecting patients' quality of life and increasing their disability. The aim of our study was to evaluate clinical and pharmacological factors associated with impaired quality of life and disability in a large cohort of IBD patients during IBD treatment.

Methods: We consecutively and prospectively recruited all IBD patients referred to the IBD Unit of the "Azienda Ospedaliera" of Padua. Demographics and clinical information were collected, and all patients completed the IBD questionnaire (IBDQ) and the IBD-Disability Index (IBD-DI) questionnaire. A multivariate regression model and Spearman's rank correlation coefficient were applied for detecting IBD-related variables relevant to disability and quality of life.

Results: We included 435 IBD patients. Multivariate regression modelling identified active disease, anaemia, presence of extraintestinal manifestations, and Crohn subtype as independent predictors for both disability and poor quality of life. We observed a strong positive correlation between IBD-DI and IBDQ (r = 0.84, p < 0.001), while there was no association with ongoing therapy or other clinical features disease-related.

Conclusions: Our study showed that disability and quality of life are both associated with active disease, anaemia, presence of extraintestinal manifestations, and Crohn phenotype while ongoing therapy seems not to be associated with disability and QoL during disease management.

PubMed Disclaimer

Conflict of interest statement

None of the authors declared any conflicts of interest or disclosed any financial relationship relevant to this publication.

Figures

Figure 1
Figure 1
Spearman correlation between IBDQ and IBD-DI scores.
See this image and copyright information in PMC

References

    1. Aggarwal A., Sabol T., Vaziri H. Update on the use of biologic therapy in ulcerative colitis. Current Treatment Options in Gastroenterology. 2017;15(1):155–167. doi: 10.1007/s11938-017-0120-8. - DOI - PubMed
    1. Guo B.-J., Bian Z. X., Qiu H. C., Wang Y. T., Wang Y. Biological and clinical implications of herbal medicine and natural products for the treatment of inflammatory bowel disease. Annals of the New York Academy of Sciences. 2017;1401(1):37–48. doi: 10.1111/nyas.13414. - DOI - PubMed
    1. Irvine J. E. Quality of life of patients with ulcerative colitis: past, present, and future. Inflammatory Bowel Diseases. 2008;14(4):554–565. doi: 10.1002/ibd.20301. - DOI - PubMed
    1. Lo B., Julsgaard M., Vester-Andersen M. K., Vind I., Burisch J. Disease activity, steroid use and extraintestinal manifestation are associated with increased disability in patients with inflammatory bowel disease using the inflammatory bowel disease disability index: a cross-sectional multicentre cohort study. European Journal of Gastroenterology & Hepatology. 2018;30(10):1130–1136. doi: 10.1097/MEG.0000000000001199. - DOI - PubMed
    1. Allen P. B., Gower-Rousseau C., Danese S., Peyrin-Biroulet L. Preventing disability in inflammatory bowel disease. Therapeutic Advances in Gastroenterology. 2017;10(11):865–876. doi: 10.1177/1756283X17732720. - DOI - PMC - PubMed

LinkOut - more resources